Neos Therapeutics Inc. (NEOS) Reaches New 52-Week Low at $6.81
Neos Therapeutics Inc. (NASDAQ:NEOS) hit a new 52-week low during trading on Thursday . The stock traded as low as $6.81 and last traded at $6.87, with a volume of 73,003 shares traded. The stock had previously closed at $7.01.
NEOS has been the topic of a number of recent research reports. Royal Bank Of Canada reduced their target price on Neos Therapeutics from $33.00 to $29.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 17th. Zacks Investment Research lowered Neos Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, May 18th. BMO Capital Markets reaffirmed a “buy” rating and issued a $15.00 target price on shares of Neos Therapeutics in a research note on Tuesday, July 19th. Finally, Wells Fargo & Co. reaffirmed a “buy” rating on shares of Neos Therapeutics in a research note on Wednesday, May 18th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $21.75.
The firm has a 50-day moving average price of $8.63 and a 200 day moving average price of $9.53. The firm’s market cap is $109.92 million.
Neos Therapeutics (NASDAQ:NEOS) last announced its quarterly earnings results on Thursday, August 11th. The company reported ($1.65) EPS for the quarter, missing the consensus estimate of ($1.16) by $0.49. The business had revenue of $1.49 million for the quarter, compared to the consensus estimate of $1.48 million. On average, equities research analysts expect that Neos Therapeutics Inc. will post ($5.38) earnings per share for the current year.
In other news, insider Juergen Martens purchased 10,000 shares of the company’s stock in a transaction on Monday, June 13th. The shares were bought at an average price of $9.90 per share, for a total transaction of $99,000.00. Following the completion of the purchase, the insider now owns 10,000 shares of the company’s stock, valued at $99,000. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
A hedge fund recently raised its stake in Neos Therapeutics stock. Marshall Wace LLP boosted its stake in shares of Neos Therapeutics Inc. (NASDAQ:NEOS) by 11.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 96,162 shares of the company’s stock after buying an additional 9,929 shares during the period. Marshall Wace LLP owned 0.60% of Neos Therapeutics worth $1,377,000 as of its most recent SEC filing.
Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).